Scott Dunseth Myers - 06 Feb 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact for Scott Myers
Issuer symbol
VRDN
Transactions as of
06 Feb 2023
Net transactions value
$0
Form type
4
Filing time
07 Feb 2023, 17:55:55 UTC
Previous filing
04 Jan 2023
Next filing
13 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Award $0 +250,000 $0.000000 250,000 06 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +1,000,000 $0.000000 1,000,000 06 Feb 2023 Common Stock 1,000,000 $35.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F2 The option vests 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.